Evidence map›Paper›PMID 42696127›Full record

ArticleJournal of gastroenterology2026

B cell receptor-associated protein 31 levels in serum-derived extracellular vesicles are associated with therapeutic response and prognosis in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a multicenter study.

Takanori Suzuki, Kentaro Matsuura, Yutaka Hashimoto, Masako Okina, Ryo Sato, Hayato Kawamura, Kiyoto Narita, Kei Fujiwara, Satoshi Narahara, Haruki Uojima and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takanori SuzukiDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Kentaro MatsuuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan. matsuura@med.nagoya-cu.ac.jp.
Yutaka HashimotoDepartment of Cell Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Masako OkinaDepartment of Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Ryo SatoDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Hayato KawamuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Kiyoto NaritaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Kei FujiwaraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Satoshi NaraharaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Haruki UojimaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hiromi KataokaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Yasuhito TanakaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Funding

Grant-in Aid for Research in Nagoya City University 2522103KAKENHI JP23K07359MEXT Project for promoting public utilization of advanced research infrastructure JPMXS0441500025
6 · The paper itself

Abstract

backgroundThere remains an unmet need for reliable biomarkers associated with therapeutic response to immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC). We retrospectively examined protein levels in serum-derived extracellular vesicles (EVs) as candidate biomarkers associated with treatment response in patients with advanced HCC.

methodsA total of 122 patients with advanced HCC treated with atezolizumab plus bevacizumab (ATZ/BEV) were retrospectively selected. The discovery group comprised 12 patients, whose serum-derived EV samples underwent comprehensive proteomic profiling by quantitative data-independent acquisition mass spectrometry. The remaining 110 patients comprised the validation group, in whom selected EV proteins were quantified by parallel reaction monitoring analysis.

resultsB cell receptor-associated protein 31 (BAP31) was identified as an exploratory biomarker associated with early treatment response. Receiver operating characteristic analysis of pretreatment log

conclusionsPretreatment BAP31 levels in serum-derived EVs may represent an exploratory biomarker potentially associated with early treatment response and prognosis in patients with advanced HCC receiving ATZ/BEV. Further validation is warranted.

Indexed as

Atezolizumab plus bevacizumab (ATZ/BEV)B cell receptor-associated protein 31 (BAP31)Extracellular vesicles (EVs)Unresectable hepatocellular carcinoma (u-HCC)

Identifiers

PMID42696127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.